Gilead Sciences (GILD)

Gilead Sciences reported Q3 earnings of $0.72 per share on net income of $673 million compared to $0.52 per share on net income of $496 million in the year ago period.
Product sales increased 23 percent to a record $1.65 billion for the third quarter of 2009, compared to $1.34 billion in the third quarter of 2008. This increase in sales was driven primarily by Gilead’s antiviral franchise, including the strong growth in sales of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) and continued growth in sales of Truvada® (emtricitabine/tenofovir disoproxil fumarate), as well as the addition of Ranexa®Â (ranolazine) to our commercial portfolio.

Oct 22 · 3:06:00 PM · Source: Press Release
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto